Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAndrew KuykendallRSRory M. ShallisJLJeffrey E. Lancet

Discussion

Loading...

Member takes

Overview

Randomized trial compares outcomes of hypomethylating agents monotherapy and venetoclax in high-risk myelodysplastic syndromes, highlighting treatment response patterns.

Key Points

  • To evaluate the effectiveness of hypomethylating agents combined with venetoclax in treating higher-risk myelodysplastic syndromes.
  • Conducted a randomized phase 3 trial analyzing HR-MDS treatments.
  • Compared outcomes for patients on hypomethylating agents alone vs. combination with venetoclax.
  • Analyses included response rates, allogeneic transplant outcomes, and survival statistics.
  • Higher overall response rate observed with the combination therapy (69.1%) compared to monotherapy (43.2%).
  • No significant survival advantage for the combination treatment across the overall cohort.
  • Potential benefits noted among specific subsets, including those with ASXL-1 mutations.

Cite This Study

Kuykendall et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d79ehttps://doi.org/10.1182/blood-2025-2072
View Full Paper
Ask AI
Bookmark
Share